ACADIA Pharmaceuticals Inc
ACAD22.200USD
-0.370-1.64%
收盘 11/10, 16:00（美东）报价延迟15分钟
3.76B总市值
14.38市盈率 TTM
关于 ACADIA Pharmaceuticals Inc 公司
Acadia Pharmaceuticals Inc. 是一家生物制药公司。该公司专注于开发和商业化药物，以满足中枢神经系统 (CNS) 疾病和罕见疾病中未满足的医疗需求。该公司拥有一系列商业阶段产品、开发中产品机会和研究项目，旨在满足中枢神经系统疾病和罕见疾病中未满足的需求。其产品线包括 NUPLAZID（匹莫范色林）、DAYBUE（曲芬奈肽）、ACP-101、ACP-204 和反义寡核苷酸 (ASO) 项目。NUPLAZID 是一种选择性血清素反向激动剂/拮抗剂，优先针对 5-HT2A 受体。NUPLAZID 专为治疗帕金森病精神病而开发。曲芬奈肽是胰岛素样生长因子 1 (IGF-1) 氨基末端三肽的一种新型合成类似物，旨在通过减少神经炎症和支持突触功能来治疗雷特综合征的核心症状。
ACADIA Pharmaceuticals Inc简介
公司代码ACAD
公司名称ACADIA Pharmaceuticals Inc
上市日期May 27, 2004
CEOMs. Catherine Owen Adams
员工数量653
证券类型Ordinary Share
年结日May 27
公司地址12830 El Camino Real
城市SAN DIEGO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编92130
电话18585582871
网址https://acadia.com/
公司代码ACAD
上市日期May 27, 2004
CEOMs. Catherine Owen Adams
ACADIA Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Director
Independent Director
102.88K
--
Dr. Adora Ndu, Pharm.D.
Dr. Adora Ndu, Pharm.D.
Independent Director
Independent Director
24.80K
+60.90%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.10K
-48.90%
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Elizabeth H. Z. Thompson, Ph.D.
Dr. Elizabeth H. Z. Thompson, Ph.D.
Executive Vice President and Head of Research and Development
Executive Vice President and Head of Research and Development
--
--
Mr. Mark C. Schneyer
Mr. Mark C. Schneyer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Edmund P. Harrigan
Dr. Edmund P. Harrigan
Independent Director
Independent Director
--
--
Mr. Thomas Andrew (Tom) Garner
Mr. Thomas Andrew (Tom) Garner
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Ms. Catherine Owen Adams
Ms. Catherine Owen Adams
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Director
Independent Director
102.88K
--
Dr. Adora Ndu, Pharm.D.
Dr. Adora Ndu, Pharm.D.
Independent Director
Independent Director
24.80K
+60.90%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.10K
-48.90%
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Elizabeth H. Z. Thompson, Ph.D.
Dr. Elizabeth H. Z. Thompson, Ph.D.
Executive Vice President and Head of Research and Development
Executive Vice President and Head of Research and Development
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q2
FY2023Q1
业务USD
名称
营收
占比
NUPLAZID
168.48M
63.68%
DAYBUE
96.09M
36.32%
暂无数据
业务
地区
业务USD
名称
营收
占比
NUPLAZID
168.48M
63.68%
DAYBUE
96.09M
36.32%
股东统计
更新时间: 10月8日 周三
更新时间: 10月8日 周三
持股股东
股东类型
持股股东
持股股东
占比
Baker Bros. Advisors LP
25.36%
BlackRock Institutional Trust Company, N.A.
10.77%
The Vanguard Group, Inc.
8.96%
RTW Investments L.P.
5.32%
State Street Investment Management (US)
3.65%
其他
45.95%
持股股东
持股股东
占比
Baker Bros. Advisors LP
25.36%
BlackRock Institutional Trust Company, N.A.
10.77%
The Vanguard Group, Inc.
8.96%
RTW Investments L.P.
5.32%
State Street Investment Management (US)
3.65%
其他
45.95%
股东类型
持股股东
占比
Hedge Fund
36.76%
Investment Advisor
34.34%
Investment Advisor/Hedge Fund
25.10%
Research Firm
3.90%
Pension Fund
1.27%
Sovereign Wealth Fund
0.91%
Individual Investor
0.56%
Bank and Trust
0.34%
Venture Capital
0.06%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
670
173.25M
102.40%
-15.51M
2025Q2
671
174.83M
104.44%
-12.86M
2025Q1
688
177.74M
106.20%
-7.86M
2024Q4
643
167.35M
100.34%
-11.57M
2024Q3
599
161.17M
97.17%
-22.69M
2024Q2
603
166.04M
100.49%
-20.26M
2024Q1
612
167.37M
101.58%
-15.73M
2023Q4
589
164.89M
100.43%
-16.10M
2023Q3
560
161.37M
98.56%
-19.17M
2023Q2
557
164.35M
101.06%
-15.99M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Baker Bros. Advisors LP
42.90M
25.43%
+18.77K
+0.04%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
18.22M
10.8%
-552.34K
-2.94%
Jun 30, 2025
The Vanguard Group, Inc.
15.24M
9.03%
+61.01K
+0.40%
Jun 30, 2025
RTW Investments L.P.
9.00M
5.33%
+455.43K
+5.33%
Jun 30, 2025
State Street Investment Management (US)
6.18M
3.66%
-815.47K
-11.66%
Jun 30, 2025
Morgan Stanley & Co. LLC
3.19M
1.89%
-1.07M
-25.06%
Jun 30, 2025
Point72 Asset Management, L.P.
3.17M
1.88%
-1.48M
-31.74%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.02M
1.79%
+69.58K
+2.36%
Jun 30, 2025
Citadel Advisors LLC
3.01M
1.79%
+2.72M
+922.43%
Jun 30, 2025
Palo Alto Investors LP
2.56M
1.52%
-100.72K
-3.78%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Alger Weatherbie Enduring Growth ETF
3.79%
iShares Neuroscience and Healthcare ETF
3.51%
First Trust NYSE Arca Biotechnology Index Fund
3.16%
Invesco Biotechnology & Genome ETF
2.22%
ALPS Medical Breakthroughs ETF
2.12%
Invesco S&P SmallCap Health Care ETF
1.69%
Virtus LifeSci Biotech Products ETF
1.63%
Invesco S&P SmallCap 600 GARP ETF
1.14%
SPDR S&P Biotech ETF
1.07%
Invesco S&P SmallCap Quality ETF
0.67%
查看更多
Alger Weatherbie Enduring Growth ETF
占比3.79%
iShares Neuroscience and Healthcare ETF
占比3.51%
First Trust NYSE Arca Biotechnology Index Fund
占比3.16%
Invesco Biotechnology & Genome ETF
占比2.22%
ALPS Medical Breakthroughs ETF
占比2.12%
Invesco S&P SmallCap Health Care ETF
占比1.69%
Virtus LifeSci Biotech Products ETF
占比1.63%
Invesco S&P SmallCap 600 GARP ETF
占比1.14%
SPDR S&P Biotech ETF
占比1.07%
Invesco S&P SmallCap Quality ETF
占比0.67%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
